Sign up Australia
Proactive Investors - Run By Investors For Investors

Creso Pharma and Virbac launches hemp‐based animal feed product in Switzerland

Virbac is one of the top 10 veterinary pharmaceutical companies in the world.
a plant
Anibidiol is a natural complementary feed

Creso Pharma Ltd (ASX:CPH) and Virbac SA (EPA:VIRP) have launched Anibidiol®, a hemp‐based complementary animal feed product in Switzerland.

Anibidiol is a natural complementary feed for companion animals containing a standardised amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant.

Creso has developed and will manufacture the product and Virbac will launch, market and promote it to veterinarians and pet owners.

Virbac is headquartered in France and is one of the top 10 veterinary pharmaceutical companies in the world.

Creso and Virbac had signed an agreement in September 2017, which will remain in effect for at least 3 years, in Switzerland and Lichtenstein.

Creso’s anibidiol®1.25 and anibidiol® 2.5 are designed for companion animals such as dogs and cats and come in proprietary granule formulations.

Anibidiol promotes the well-being of the animal by supporting its immunity and natural defence system. The product also supports the pet’s balanced behaviour.

The recession-resistant worldwide animal health market is valued at circa US$30 billion.

It is worth noting that 41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).

Creso’s share price increased circa 45% during the past one month, last closing at $0.80.





Register here to be notified of future CPH Company articles
View full CPH profile View Profile

Creso Pharma Ltd Timeline

Newswire
March 20 2017

Related Articles

eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use